+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Failure of a dengue 1 sub-unit vaccine to protect mice against a lethal dengue virus infection

Failure of a dengue 1 sub-unit vaccine to protect mice against a lethal dengue virus infection

American Journal of Tropical Medicine and Hygiene 39(5): 511-518

Mice immunized with DEN-1 pre-matrix protein produced antibody which reacted with dengue virus infected cells and intact virions but failed to neutralize virus in vitro or in vivo. Newborn mice passively immunized with anti-DEN-1 pre-matrix antibody also failed to survive intracerebral infection with 100 LD50 of any dengue virus serotype.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007342593

Download citation: RISBibTeXText

PMID: 2973756

Related references

Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. American Journal of Tropical Medicine and Hygiene 41(5): 576-580, 1989

Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. American Journal of Tropical Medicine and Hygiene 36(2): 427-434, 1987

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13(13): 1251-1258, 1995

A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Vaccine 36(14): 1846-1852, 2018

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harbor Perspectives in Biology 10(6):, 2018

Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. Journal of Virology 64(9): 4356-4363, 1990

Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection. Human Vaccines and Immunotherapeutics 12(9): 2327-2333, 2016

Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. Journal of Virology 79(12): 7300-7310, 2005

Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. Journal of Infectious Diseases 203(1): 103-108, 2011

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. Journal of Virology 74(17): 8094-8101, 2000

Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences. Applied Microbiology and Biotechnology 100(1): 125-133, 2016

The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Asian Pacific Journal of Allergy and Immunology 33(3): 182-188, 2015

The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Review of Vaccines 15(7): 795-798, 2016

Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Virology Journal 8: 398, 2011

Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. Journal of General Virology 69: 2101-2107, 1988